Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesStocksEarnInstitutionAI & More
Brixmor Property Slate Acquisition Seen as 'Rock Solid' Investment, UBS Says

Brixmor Property Slate Acquisition Seen as 'Rock Solid' Investment, UBS Says

MT newswireMT newswire2026/09/29 17:03
01:03 PM EDT, 09/29/2026 (MT Newswires) -- Brixmor Property's (BRX) acquisition of Slate Grocery REIT is a "rock-solid" investment case, UBS Securities said. Brixmor considers Slate a portfolio of quality shopping centers anchored by grocery stores that are fundamentally under-managed, highlighting multiple avenues for growth, according to the note Monday. The company directly acquired 23 assets across Florida, Georgia, and the Carolinas that best fit its investment criteria, which include "strong grocer anchors, attractive Sunbelt markets, redevelopment opportunities, and rent-growth potential," UBS analysts said. Avenues for growth include boosting the assets' small-shop occupancy from the current 88% level and improving the contractual rent escalators. Since in-place rents are below Brixmor's existing portfolio average by over 30%, the company can also capture mark-to-market rent opportunities, the analysts added. Brixmor can implement the asset-repositioning playbook it has used over the past 10 years, and the analysts are confident that the company can generate long-term net operating income growth of at least 4% from the portfolio, consistent with its long-term growth expectations. UBS has a buy rating on the company's stock, with a price target of $37. Shares of Brixmor were down 1.3% in Tuesday afternoon trading. Price: 27.63, Change: -0.38, Percent Change: -1.34
0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

Former BioNTech executive leads Bambusa Therapeutics (BBTX.US) in sprint to Nasdaq, "boosting" eczema drug trials

Bambusa Therapeutics Inc. has filed for an initial public offering, planning to raise funds for clinical trials of treatments for eczema and other inflammatory diseases.

智通财经•2026/10/10 06:21